 |
 |
 |
 |
 |
 |
News from SGC
Posted on Friday 15th of May 2020
Posted on Friday 15th of May 2020
SGC Director, Aled Edwards, speaks to The Future Economy on why Open Science is important in fighting COVID-19, and other related questions, in their series "The COVID-19 Rebound". You can see the full interview here: https://thefutureeconomy.ca/interviews/aled-edwards/
Posted on Friday 1st of May 2020
We determined the structure of the TASK-1 potassium ion channel. Mutations in TASK-1 are linked to pulmonary arterial hypertension.
TASK-1 has an unusual X-gate, consisting of two crossed helices. This type of gate is not present in related potassium channels and explains the low activity of TASK-1. We also crystallised TASK-1 in complex with inhibitors and found that they bind in the central cavity, trapped by the X-gate.
This work is a collaboration with Bayer AG and University of Marburg.
Posted on Thursday 9th of April 2020
(Chapel Hill, N.C.— April 7, 2020) — Today, the Structural Genomics Consortium (SGC), the University of North Carolina at Chapel Hill and the Eshelman Institute for Innovation, announce the launch of the Rapidly Emerging Antiviral Drug Development Initiative (READDI), a global organization formed to discover and develop drugs to put “on the shelf” for clinical trial testing in anticipation of future viral pandemics.
Posted on Monday 2nd of March 2020
Launch of a New Phase 2 Clinical Trial “STOPFOP”
The Saracatinib trial to prevent Fibrodysplasia Ossificans Progressiva (STOPFOP) will begin recruitment in March 2020.
Posted on Friday 28th of February 2020
February 28, 2020
The Chordoma Foundation (CF) and The Mark Foundation for Cancer Research (MFCR) announced today a two-year, $1.4M partnership with a team of researchers at three institutions to develop new treatments for chordoma, a rare and difficult-to-treat bone cancer. The researchers will focus on creating the first drugs to inhibit a protein known as brachyury.
Posted on Monday 2nd of December 2019
Photo: CHERYL ARROWSMITH AND LEVON HALABELIAN
December 2, 2019 (Toronto)
Posted on Tuesday 1st of October 2019
SGC and collaborating institutions will lead development of openly distributed tools to test the efficacy of Alzheimer’s therapies and rapidly share results
The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a grant expected to total $37.5 million over five years to establish the Open-AD Drug Discovery Center. Led by Emory University, the Center includes investigators at Sage Bionetworks, Structural Genomics Consortium (SGC), Stanford University, Oxford University, and University of North Carolina.
Posted on Friday 10th of May 2019
A new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease.
The prototype treatment could also offer hope for patients with the rare and devastating ‘stone man syndrome’ – in which muscles and ligaments turn to bone.
Scientists at The Institute of Cancer Research, London, led research with an international team of colleagues, finding that the new drug class can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice.
Posted on Wednesday 20th of March 2019
This event is supported by the NIHR Oxford Biomedical Research Centre.
Pages
